乐普生物-B（02157）今日盘中大涨5.09%，引起市场广泛关注。该股价走势强劲，主要受到公司发布的2025年上半年业绩报告的积极影响。
根据公司最新发布的财报，乐普生物在2025年上半年实现了显著的业绩增长。公司收入达到4.66亿元，较去年同期的1.33亿元同比增长3.5倍。更值得注意的是，公司净利润达到2930万元，相比去年同期亏损1.97亿元，首次实现扭亏为盈。这一业绩表现使乐普生物成为港股18A创新药企中为数不多率先实现盈利的公司之一。
乐普生物的业绩改善主要得益于其"左手抓BD、右手抓产品销售"的策略。公司的首个商业化产品普佑恒®（普特利单抗注射液）实现销售收入1.51亿元，较上年同期增长58.8%。此外，公司通过多元化BD策略实现出海，上半年实现相关收入3.09亿元。这些因素共同推动了公司的业绩增长和现金流改善，上半年公司经营活动的现金净流入为4670万元，而去年同期为现金净流出1.15亿元。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.